Introduction: Why Conventional Mutagenicity Models Are Inadequate for NDSRIs The regulatory complexity associated with N-Nitrosamine Drug Substance-Related Impurities (NDSRIs) extends […]
Introduction: Anti-Drug Antibody (ADA) Assay Development Services play a critical role in evaluating the immunogenicity of biologic therapies. As biologics
Introduction: Why CRO Selection Is a Regulatory Decision, Not Just a Scientific One When sponsors prepare regulated bioanalytical services for
Regulated Bioanalytical Services for NDA and BLA Submissions: What to Look for in a CRO Read More »
Introduction: The Most Overlooked Challenge in E&L Science Unknown Peak Identification in Extractables and Leachables (E&L) testing is among the
How to Investigate Unknown Peaks in Extractables & Leachables Study Read More »
Introduction: Extractables and Leachables from Elastomeric Closures are a major focus area in pharmaceutical packaging and regulatory compliance because elastomeric
Extractables and Leachables from Elastomeric Closures: Regulatory Expectations Read More »
Introduction: The Analytical Choice That Shapes Biosimilar Comparability In biosimilar development, selecting the appropriate proteomics strategy is far more than
Top-Down vs Bottom-Up Proteomics for Biosimilars: Which Approach is Better? Read More »
Introduction: The rapid expansion of GLP-1 receptor agonist therapeutics has increased the need for robust GLP-1 Biosimilar Characterization strategies. Peptide
Introduction: Why Solvent Selection in Extractables Studies Is a Regulatory Science Decision One of the most overlooked variables in extractables
Solvent Medium Selection in Extractables Studies and Why They Matter Read More »
Introduction: Why Nitrosamines Require a Distinct Focus Within ICH M7 Genotoxic Impurity Testing When ICH M7 was finalized in 2014,
Genotoxic Impurity Testing: Where Nitrosamines Fit Within the Broader ICH M7 Framework Read More »
Introduction: Why Late-Phase Bioanalysis Requires a Different Approach As a clinical development program progresses into Phase II and Phase III,
Bioanalytical CRO Services for Phase II and Phase III Clinical Trials Read More »
